8:20 am Chair’s Opening Remarks

Leveraging Data & Trends in Biomarkers & Diagnostics

8:30 am Working Together to Enable Solutions to Reach Patients: Maximizing the Utility of Data


Working Together to Enable Solutions to Reach Patients: Maximizing the Utility of Data

  • The move towards molecularly characterizing patients and retrospective analysis
  • Designing guidance to appropriately share data internally and improve awareness of published information
  • Addressing industry concerns on big data and privacy and implications for improving pre-competitive data sharing

9:00 am Comprehensive Genomic Profiling Across the Continuum of Care: Are We There Yet?

  • Daniel Simon Senior Vice President, Biopharma Business Development, Guardant Health


  • The roles of liquid and tissue in late stage cancer
  • Monitoring therapy response using ctDNA
  • A tissue-agnostic approach for MRD in earlier stage cancer

9:30 am Mixed Models of Commercialization for Companion Diagnostics

  • Kate Knobil Chief Medical Officer, Agilent Technologies
  • Mark Li Chief Executive Officer, Resolution Bioscience


  • How global markets drive different models for commercialization
  • Clinician/Market need for optionality
  • Utilizing multiple diagnostic technologies together to help clinicians improve patient management, based on: Disease/indication, sample type & market access/availability

10:00 am Reducing Time to Treatment Initiation in Precision Oncology: The Impact of Fast NGS Testing

  • Luca Quagliata Vice President, Global Head of Medical Affairs, Thermo Fisher Scientific


• TF solutions for CDx in precision oncology
• Importance of short turn around time in delivering molecular profiling
• Enabling HCPs to improve current clinical patient management

10:30 am Diagnostic Advances for Rare Diseases, Now, & in the Future

  • Tom Defay Deputy Head, Diagnostics Strategy & Development, Alexion Pharmaceuticals, Inc.


  • Overview of diagnosis in rare disease
  • Advances in genetics to increase clinical suspicion
  • Advances in phenotype characterization and screening to increase clinical suspicion
  • Combining genotype and phenotype to aid in diagnostics

11:00 am Speed Networking Break


Utilize this opportunity to make meaningful connections with some of the industry’s greatest minds to hear the latest thinking on biomarkers and diagnostics and identify new technologies with potential to innovate your pipeline

Moving Biomarkers Towards the Clinic

Broadening the Scope of Validated Biomarkers

11:30 am Driving Biomarker Discovery: The UK Biobank Pharma Proteomics Project


  • Analysis of ~1,500 circulating proteins to be analyzed from 53,000 patient blood samples
  • Enabling better understanding of the association between genetic variation and circulating protein levels to support innovative drug development linking genetics and human disease
  • Providing pre-competitive data mapping the levels of human proteins traditionally difficult to identify and quantify at scale

12:00 pm High Quality Liquid Biopsies- Capture the Molecular Reality


  • How Indivumed collects longitudinal liquid biopsies
  • Indivumed´s liquid biobank: tumor entitites and therapies
  • Benefits of Indivumeds Liquid Biopsy Biobank

12:10 pm Building an Emerging Technologies Model from R&D to Commercialization by Leveraging Foundational Biomarkers and Clinical Dx Evidence

  • William Powell Director Product Technology and Strategy, Leica Biosystems


  • Enabling novel technologies to answer clinical questions in the translational medicine space
  • Transition to CDx development and regulatory
  • Importance of clinical evidence to commercialization

12:40 pm Reverse Engineering Translational Biomarkers For Novel Breast Cancer Subtypes


  • Strategic overview on logistics for high quality biomarker translation
  • Reverse engineering biomarker selection going from protein to gene expression
  • Identification of ‘upstaging’ ER+ subtypes which impacts therapy selection and outcome

Clinical Biomarker & Assay Development

Overcoming Complexities in New Biomarker Therapeutic Strategies

11:30 am The Use of Biomarkers to Confirm Mode of Action & Inform Combination Strategy for PRS-343 in Her2-Low Gastric Cancer in Combination with Tucatinib

  • Markus Zettl Senior Director of Immuno–Oncology, Pieris Pharmaceuticals GmbH


  • PRS-343, the first bispecific to enter the clinic engineered to specifically activate 4-1BB in the tumor microenvironment is well tolerated and demonstrated durable anti-tumor activity in heavily pre-treated patient population including patients with “cold” tumors
  • Biomarkers confirm the mode of action of PRS-343 with a clear dose-dependent increases in CD8+ T cells in the tumor and soluble 4-1BB in plasma
  • Preclinical in vitro experiments showed that PRS-343 activity can be enabled and enhanced by Tucatinib in the situations with low HER2 expression
  • Preliminary evidence of activity was also demonstrated in HER2 low patients

12:00 pm Power of Tumor-Informed & Personalized Assays to Drive High Sensitivity


  • Why personalized tumor-informed assays optimize sensitivity and specificity
  • Latest publications and data including IMvigor 010
  • What clinical trial designs are possible with a personalized tumor-informed assay

12:30 pm Evaluating Neoantigen Immunotherapies in the Clinic


  • Utilizing advances in genomic analysis and interpretation for therapeutic development
  • Selection of therapeutically useful neoantigens for immunization
  • Integrating immune monitoring and cell free DNA (cfDNA) to evaluate immunotherapies clinically

Commercialization in the CDx Industry

CDx Development Alignment with Clinical & Commercial Goals

11:30 am Strategies & Considerations for CDx Development in Early Phase Oncology Studies


• Best practices and key learnings from early CDx development
• Aligning with the clinical development plan and timing of engagement with a diagnostic manufacturer
• Understanding the prevalence of your biomarker and approaches for patient selection in Ph1 studies

12:00 pm Combining AI and Comprehensive Molecular profiling to deliver the next generation of Molecular Diagnostics

  • Brian Kelly Vice President Global Biopharma and CDx Strategy, Caris Life Sciences


  • Summary of Caris offerings for comprehensive NGS solutions with Whole Exome/Whole Transcriptome for all solid tumor, liquid biopsy and Haematological specimens in a CAP/CLIA offering
  • Update on progress in the develop of the Caris CDx companion diagnostic program
  • Examples of AI-enabled advanced biomarker signatures for CRC and Cancer of Unknown Primary

12:30 pm Post Market Activities: Innovative Commercial Strategies for Rare Oncology Tumors


• Real World Data to gain scientific credibility
• Innovative strategies to broaden assay adoption and utility
• Key stakeholders to engage through implementation cycle
• Additional to education, what strategies can companies use to increase adoption?

1:00 pm Regulation Group Discussion: IVDR & Europe – How are you Planning Ahead?


This roundtable session will enable attendees to participate in discussions surrounding forward planning for IVDR measures being implemented in Europe in May 2022. With the potential to cause major disruption to CDx development and clinical trials, join with your peers to learn why the topic is so front-of-mind. You will have the opportunity to:

  • Discuss what IVDR means for clinical planning to inform your data collection and study design
  • Hear how your precision medicine industry are preparing for the soon-approaching deadline
  • Address predicted challenges post-IVDR to plan strategies to overcome these to fulfil global drug-dx expansion goals

Generating Evidence Data to Translate New Biomarkers to the Clinic

2:00 pm Overcoming Sample Quantity Limitations


  • Can biospecimen databases help overcome limited access to genomic & proteomic data?
  • Utilizing NGS and addressing privacy concerns challenging personalized approaches and overcoming challenges of a small patient population

2:30 pm A Spatial Biology Approach for Biomarker Studies In Immuno-Oncology

  • Gavin Gordon Vice President, Clinical Market Development, Akoya Biosciences


  • Current limitations of predictive biomarkers in immunooncology
  • Potential for multiplexed immunofluorescence to improve biomarker strategies in immuno-oncology
  • Partnering with Akoya to support translational and clinical research

3:00 pm Ultra-sensitive Biomarker Assay Development for Translational Research & Precision Medicine


• Biomarker detection strategies with best-in-class sensitivity from solid tumor and liquid biopsy

• From research use only to clinical trial; assay development and validation, clinical specimen testing, and manufacturing services

• Insights into NuProbe’s assay development programs addressing challenging translational research questions

3:30 pm Biomarker Discovery and the Quality of Biological Samples

  • Zisis Kozlakidis Head of Laboratory Services and Biobanking, International Agency for Research on Cancer/World Health Organization (IARC/WHO)

Early Intervention for Better Patient Outcomes

2:00 pm ctDNA Response as an Earlier Indicator of Benefit & for MRD Monitoring

  • Chris Abbosh Principal Clinical Fellow, AstraZeneca Clinical Fellowship, University College London


  • How to measure and assess across a number of biomarkers
  • Integrating data to support confidence in conclusions
  • The value of prognosis prediction to determine and develop better treatment options

2:30 pm Liquid Biopsies in Cancer Drug Development & Clinical Use


  • Evaluating current evidence on innovative technologies including circulating tumor cell and circulating tumor DNA methods
  • Improving detection, prognosis, and disease monitoring as well as drug development

3:00 pm Harmonization of Novel Biomarkers to Support Clinical Applications: TMB Case Study

  • Mark Stewart Vice President, Science Policy, Friends of Cancer Research


  • Highlighting industry collaboration to set industry standards to enable the correlation of biomarkers with clinical outcome
  • Enabling the analytical validation of liquid biopsies to define performance metrics needed for precise patient therapy decision making
  • Overcoming sensitivity and specificity assay challenges impacting liquid biopsy clinical utility

3:30 pm Personalized ctDNA MRD Assays – Redefined

  • Tim Forshew Head of Science and Innovation & Co-Founder, Inivata
  • Greg Jones Senior Director of Medical Affairs, Inivata


Essential approach(es) for improved oncology clinical trial design and companion diagnostic (CDx) testing

Ensuring Patient Access in Routine Practice

2:00 pm Identifying Clinician and Patient Barriers to Guideline-Concordant Biomarker Testing

  • Nikki Martin Director, Precision Medicine Initiatives, LUNGevity
  • Janelle Schrag Assistant Director, Research Programs, Association of Community Cancer Centers
  • Antonella Cardone Executive Director, European Cancer Patient Coalition


  • Profile a multi-phase initiative that focuses on cataloging barriers to biomarker testing among underserved lung cancer patients and developing a patient-and-clinicianapproved intervention to bridge testing gaps
  • Learn about key findings from the provider and patient research
  • Hear more about how an intervention to address gaps in biomarker testing access can be utilized

2:30 pm Generating Proper Reliable Evidence to Translate New Medicines/Interventions to the Clinic – The Current Reimbursement Landscape

  • Eugean Jiwanmall Senior Research Analyst for Medical Policy & Technology Evaluation, Independence Blue Cross


  •  What are the current technical parameters, clinical validity, & clinical utility needs to meet standards
  • What does the current diagnostic testing landscape look like and what is the current framework for new medicines & interventions to be introduced
  • What perspectives should be considered for CDx reimbursement and what is the basis for securing these

3:00 pm Panel Discussion Demonstrating Clinical Utility to Engage with Payors & Secure Reimbursement


  • Highlighting reimbursement requirements needed to show clinical utility for patient response over survival indicators
  • Trial design to factor in payor requirements – resulting in lower costs and lengthy trial periods
  • Uniting payor, hospital testing labs, IVD sponsor perspectives for improved testing access

4:00 pm Networking Break


  • With over half of drugs now approved supported by a biomarker, remain connected with your CDx community with the opportunity for 1:1 networking to stay ahead of the curve on the technological advances that could take your drugs to market
  • If you are new to the CDx space and need advice, get in touch and we can facilitate!

Applying AI & Advanced Analytics to Progress Medicines

4:30 pm Leveraging Machine Learning & AI in Translational Medicine

  • Andrew Beck Co-Founder & Chief Executive Officer, Path AI


  • Prioritizing the improvement of patient outcomes with reliable AI-Powered technology to provide patients with the most accurate diagnosis and efficient treatments
  • Our translational platform identifies and analyzes new cellular and tissue patterns to find pathology-based features that are used to gain novel insights across all phases of drug development and therapeutic areas at scale
  • Eliminate observer variability and improve patient selection and stratification to ensure the right patient is included in every trial and to increase the probability of trial success

5:00 pm Utilizing AI Tools for CVD & Rare Disease Drug Development


  • AI approaches to generate insight in rare disease where patient subsets are small
  • Addressing challenges to integrating AI systems into biological and pre-clinical workflows
  • Improving feasibility of AI for better disease modelling and drug targeting

5:30 pm Closing Remarks & Close of the 11th World Clinical Biomarkers & CDx Summit 2021